Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Devon B Dubose"'
Autor:
Mathewos Tessema, Steven A. Belinsky, Wendy W Dye, Wenshu Chen, David Revelli, Devon B Dubose, Christin M. Yingling, Michael Burke, Philip J. Kuehl
Publikováno v:
Drug Delivery, Vol 28, Iss 1, Pp 767-775 (2021)
Drug Delivery
article-version (VoR) Version of Record
Drug Delivery
article-version (VoR) Version of Record
Topotecan is potent anti-cancer drug approved for various malignancies but hematopoietic toxicities undermine its wider application and use of its most effective dose. This study aims to improve these limitations through inhalation-delivery. The phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a5a00120d912c6021195b3c083e91f2
https://doaj.org/article/dc02d998734d408f9f931094d9d32474
https://doaj.org/article/dc02d998734d408f9f931094d9d32474
Autor:
Andrew P. Gigliotti, Michael Burke, Philip J. Kuehl, Devon B Dubose, Steven A. Belinsky, David Revelli, Mathewos Tessema, Marcie J. Grimes
Publikováno v:
Drug Delivery, Vol 25, Iss 1, Pp 1127-1136 (2018)
Drug Delivery
Drug Delivery
Intravenous (IV) topotecan is approved for the treatment of various malignancies including lung cancer but its clinical use is greatly undermined by severe hematopoietic toxicity. We hypothesized that inhalation delivery of topotecan would increase l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e104fdcaf2a602ad6aa094c7671cabe
https://doi.org/10.1080/10717544.2018.1469688
https://doi.org/10.1080/10717544.2018.1469688
Autor:
Larry M Mallis, David Revelli, Steven A. Belinsky, Carmen S. Tellez, David T. Vodak, Thomas H. March, Michael Burke, Aaron M. Badenoch, Marcie J. Grimes, Philip J. Kuehl, Maria A. Picchi, Wendy W Dye, Devon B Dubose, Tyler Sniegowski, Mathewos Tessema
Publikováno v:
British Journal of Cancer
Background Epigenetic therapy through demethylation of 5-methylcytosine has been largely ineffective in treating lung cancer, most likely due to poor tissue distribution with oral or subcutaneous delivery of drugs such as 5-azacytidine (5AZA). An inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9766125b78ed3fd6298e0ead96ff763c
https://pubmed.ncbi.nlm.nih.gov/32103148
https://pubmed.ncbi.nlm.nih.gov/32103148
Autor:
Vidadi Yusibov, Jeffrey F. Breit, Michael Burke, Stephen J. Streatfield, Jessica A. Chichester, Devon B Dubose, April Horsey, Slobodanka D. Manceva, R. Mark Jones
Second generation anthrax vaccines focus on the use of recombinant protective antigen (rPA) to elicit a strong, toxin neutralizing antibody responses in immunized subjects. The main difference between the rPA vaccines compared to the current licensed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8078e91d2ee759db7e2d9c48a8285e2
https://publica.fraunhofer.de/handle/publica/247576
https://publica.fraunhofer.de/handle/publica/247576
